IFNA17 and cryohydrocytosis: We investigated the expression profiles of these selected miRNAs as novel biomarkers in serum of CHC genotype 4 patients, their correlations with clinical data, and whether their pretreatment levels would predict patient response to PEG-IFN-α/RBV therapy.